Liposomes useful for drug delivery
The present invention provides liposome compositions containing substituted ammonium and/or polyanion, and optionally with a desired therapeutic or imaging entity. The present invention also provide methods of making the liposome compositions provided by the present invention.
1. A liposome composition comprising irinotecan, inositol hexaphosphate, and one or more lipids, wherein the millimoles of irinotecan per gram of total liposomal lipids is between 0.8 and 1.3, and the liposomes in the composition entrap irinotecan and inositol hexaphosphate.
2. The liposome composition of claim 1 , wherein the liposomal lipids comprise one or more neutral phospholipids and cholesterol.
3. The liposome composition of claim 2 , wherein the neutral phospholipid and cholesterol are in a mole ratio of about 3:2.
4. The liposome composition of claim 1 , wherein the composition comprises a polyethylene glycol phosphatidylethanolamine.
5. The liposome composition of claim 4 , wherein the polyethylene glycol phosphatidylethanolamine comprises a poly(ethylene glycol) moiety having a molecular weight from about 250 to about 20,000.
6. The liposome composition of claim 1 , comprising distearoylphosphatidylcholine, cholesterol, and N-(methoxy-poly(ethylene glycol) (PEG molecular weight from 500 to 5,000)-oxycarbonyl)-distearoylphosphatidylethanolamine in a mole ratio of 3:2:0.015.
7. The liposome composition of claim 1 wherein the liposomes comprise one or more lipids comprising distearoylphosphatidylcholine, cholesterol, and N-(methoxy-poly(ethylene glycol) (PEG molecular weight 2000)-oxycarbonyl)-distearoylphosphatidylethanolamine in a mole ratio of 3:2:0.015.
8. The liposome composition of claim 1 , wherein the liposomes have a mean size of 104.3±39 nm as determined by volume-averaged mean of the liposome size distribution by quasi-elastic light scattering (QELS) using Gaussian model.